TERT and breast cancer: The fact that TERT promoter mutations have been identified in urine years prior to the primary clinical diagnosis of BC and in some relapse-free patients under surveillance reflects the early occurrence of the mutations in the primary carcinogenic and in the relapse processes, providing a window of opportunity for early molecular detection and intervention.